Last update 22 Mar 2025

Tamoxifen

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
DARE-VVA1, PT-101
Target
Action
modulators
Mechanism
ERs modulators(Estrogen receptors modulators)
Therapeutic Areas
Inactive Indication-
Originator Organization
Active Organization
Inactive Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC26H29NO
InChIKeyNKANXQFJJICGDU-QPLCGJKRSA-N
CAS Registry10540-29-1

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Vaginal DiseasesPhase 1-21 Sep 2023
DyspareuniaIND Approval
United States
07 Dec 2023
Vulvovaginal atrophyIND Approval
United States
07 Dec 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
18
(Tamoxifen)
aowrytcnvn(eaadusfhoo) = jkvcgpveeh zmqephuyye (ynogmtxjjw, 0.194)
-
05 Dec 2024
Placebo Oral Tablet
(Placebo)
aowrytcnvn(eaadusfhoo) = thsczvfcnf zmqephuyye (ynogmtxjjw, 0.274)
Not Applicable
-
Tamoxifen users
uvsfaprtqj(hisgioudnp) = tueodlxxni atkbxrllfo (emjztcfmti )
-
01 Sep 2023
Non-tamoxifen users
uvsfaprtqj(hisgioudnp) = vtaqldpbrn atkbxrllfo (emjztcfmti )
Not Applicable
-
(Uterine cancer patients)
lhosgmdtcc(qqzmqmzuwe) = mwvfrflamq ylkwmwphqo (zbvuqqtfpw )
-
01 Sep 2023
Not Applicable
-
Oral Tamoxifen 10mg twice daily
wcixfhumvn(kaqhxteemk) = A PI was done, and the patient was started on AGM ttilcdnhib (zcgrvrwmlb )
-
06 Mar 2019
Topical AGM
Not Applicable
-
-
(Breast Cancer First)
bchgwokctz(yoxhbtzzst) = ugxtrqjchi epdtsmxnuo (nrezlvmvnt )
-
01 Jun 2016
(Endometrial Cancer First)
bchgwokctz(yoxhbtzzst) = jzpretfien epdtsmxnuo (nrezlvmvnt )
Phase 3
19,747
Tamoxifen 20 mg/day
giffuuxcxl(ndkpkievtx) = mwolbzdfsw ariizbyhec (fozwfxokun )
-
01 Apr 2013
giffuuxcxl(ndkpkievtx) = zdezgfdthx ariizbyhec (fozwfxokun )
Not Applicable
-
kfnkdlnodw(hzoqhhxwio) = cqjpmylyas sohowbqecu (epnotismrj )
-
01 Nov 2010
No Tamoxifen
kfnkdlnodw(hzoqhhxwio) = ifurggitdc sohowbqecu (epnotismrj )
Phase 3
19,747
Tamoxifen
nntjmwscki(onmvzulmwi): RR = 0.7 (95% CI, 0.54 - 0.91)
-
01 Jan 2009
Phase 3
371
bgrpsgptpc(zwevqwwnim) = tqrtgeydms nhvfpdgpuu (fcaqwgafah )
-
20 Oct 2008
bgrpsgptpc(zwevqwwnim) = txaswhnwua nhvfpdgpuu (fcaqwgafah )
Not Applicable
1,551
wyeaalgwap(wlcsmyvjgp) = Women who reported hot flashes at baseline were less likely to develop recurrent breast cancer than those who did not report hot flashes lndoolyihp (qatogqpczh )
-
01 Apr 2008
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free